WHO: Globally confirmed cases of new coronary pneumonia exceed 254.84 million

According to the latest real-time statistics of the World Health Organization, as of 16:27 on November 18, Central European time (23:27 on November 18, Beijing time), there were a total of 254847065 confirmed cases of new coronary pneumonia worldwide and a total of 5,120,712 deaths. On the 18th, there were 555,946 new confirmed cases of new coronary pneumonia worldwide, and 7,990 new deaths.

2021-11-19

New crown epidemic accelerates spread, Italy introduces new regulations for public transportation control

In response to the rebound of the new crown epidemic, on the 15th local time, the Italian Ministry of Health and the Ministry of Infrastructure and Sustainable Transport jointly issued new regulations requiring the strengthening of epidemic control in the transportation and logistics links. Control measures include: checking the new crown "digital green pass" before passengers boarding the train; once the passengers are found to have symptoms of new crown pneumonia on the train, the railway police and the health department can request the train to stop and take further measures; taxis and other non-fixed On line public transportation, passengers should avoid taking the same row of seats as the driver, and there should be no more than two passengers in the car. The driver should wear a mask and hold a "digital green pass"; the station waiting hall should limit the number of people and keep it strictly 1 meter Social distancing. 　  The Italian Epidemiological Association issued a report on the same day that the epidemic is spreading very rapidly in the country. The data on November 13 shows that the effective number of infections (Rt) in the country has risen to 1.42 that day, and the effective number of infections in all regions has exceeded 1. At the current rate of development, in two weeks, the country will have 5 regions with an incidence rate of more than 250 cases per 100,000 people, and another 8 regions with an incidence rate of more than 150 cases per 100,000 people.

2021-11-16

More than 300,000 women will continue to receive education in an Afghan province to reset a girls' middle school

Haiwaiwang, November 9th. Afghan media reported that, according to the country’s Herat Province Teacher Selection Committee, after close to three months, the province has reopened girls’ schools for all female students. In the past few months, only girls under the 6th grade were allowed to go to school; now, Herat Province allows girls and young women from 7th to 12th grades to go to school. According to news from the Afghan Dawn News Network on the 8th, the Herat Provincial Teachers Selection Committee stated that the decision was made after a month’s discussion with the girls’ school officials and local Taliban officials in Herat. This decision allowed more than 300,000 girls continue to receive education. At the same time, the girls said that they are happy to resume their education. 　　 According to data from the Department of Education in Herat, there are more than one million students in the province receiving education, and more than half are girls. Earlier, the Acting Minister of Education of Afghanistan stated that schools in all provinces of Afghanistan will be reopened and the Taliban will allow girls to go to secondary school within two months.

2021-11-09

The real anti-new crown drug is here! Is it far from ending the epidemic?

Nearly two years after the emergence of the new crown epidemic, oral drugs against the new crown virus began to enter the harvest period. On November 4th, the US pharmaceutical company Merck announced that its small molecule drug Molnupiravir has been approved by the UK Food and Drug Administration, becoming the world's first oral drug approved for the treatment of mild to moderate neocorona infections in adults. Only one day later, Pfizer Pharmaceuticals of the United States disclosed the results of the clinical trial of Paxlovid, an oral drug for new crowns developed by it. Taken in the early stages of symptoms, the drug can reduce the risk of hospitalization or death of patients with new crowns by 89%. As soon as the news came out, the new crown vaccine and neutralization were on the market. The stocks of antibody and detection related sectors fell in response. After the results of Pfizer's new crown oral drug test were published, a scientist in the field of drug development wrote on the "Science" website: On our way to fight the new crown virus, there has been another turning point-we already have a vaccine, and now we have it again. The drugs that can be taken in the early stage of the disease, think about how many infectious diseases can have so many weapons! After the COVID-19 pandemic lasted for nearly two years, doctors found that they still had few weapons: the drugs used to treat COVID-19 either did not directly deal with the COVID-19 virus and did not know the effect; either they needed injections and could only be used in medical treatment. Institutional use. However, there is no convenient, cheap, and easy-to-obtain oral medicine for people with mild or moderate infections who do not need to be hospitalized. "Nature" magazine wrote that at first, the exploration in this area was mainly focused on searching among the existing "old medicines", and the most effective one was found to be dexamethasone. It reduces the risk of death for critically ill patients using ventilators by a third. Dexamethasone is a steroid drug designed to suppress the excessive inflammatory response of the most severely ill people. It has not been approved for use in the new crown, but it is widely used to treat the most severely ill patients with the new crown. Wang Haoran, founder of Newland Biotech, used to work as a scientist at Novartis, an international pharmaceutical company. He told China News Weekly that many "old drugs and new applications" such as dexamethasone, hydroxychloroquine, and famotidine have been proven to have some effects. It is also used in clinical treatment, but it only shows a good effect on some patients, and it cannot be regarded as a specific medicine due to its high toxicity or unclear mechanism. There are also some pharmaceutical companies and research teams who count the compounds in their "stocks" that may be useful for the new crown virus. Although these are not designed for the new crown, they at least make sense in terms of mechanism. So far, among these drugs currently approved by the US FDA, only Gilead’s Remdesivir requires injection. In a phase III clinical trial, the researchers found that compared with placebo, remdesivir can shorten the overall recovery time of hospitalized patients by 5 days. About half of the COVID-19 hospitalized patients in the United States are now treated with Redecive. But some doctors say that regardless of whether patients receive the treatment, they often recover very slowly in the clinic. Soon, doctors’ "toolbox" will have two drugs specifically developed for the new crown: orange Molnupiravir, and red and black Paxlovid with the words "COVID-19" printed on them. Both are capsules. It is very similar to the course of treatment. On October 1, Merck announced that its oral anti-coronavirus drug Molnupiravir (Chinese translation "Monupivir") Phase III clinical trial data is optimistic. The trial enrolled 775 subjects. The enrollment conditions included patients with mild to moderate new coronary pneumonia, the onset of symptoms did not exceed 5 days at the time of enrollment, and they were all accompanied by at least one risk factor related to poor disease outcome, such as Age, obesity, diabetes, heart disease. Interim results show that monupivir reduces the patient's risk of hospitalization or death by 50%. On the 29th day after randomization, the proportion of hospitalized deaths in patients receiving monupivir was 7.3% (28/385), compared with 14.1% (53/377) in the placebo group. During the 28 days of follow-up, no deaths were reported in the monupivir treatment group, compared with 8 deaths in the placebo group. 　　 "The name Molnupiravir is named after Mjollnir, the ‘Thor’s Hammer’. This drug is a hammer against the new coronavirus, no matter what variant the new coronavirus will evolve." Merck’s global head of R&D introduced this. This compound is a nucleoside analog. Its mechanism of action is to combine with the RNA polymerase of the

2021-11-08

U.S. daily increase of more than 58,000 diagnoses, accumulatively more than 46.87 million

Overseas Network, November 2 According to Worldometer's real-time statistics, as of about 6:30 on November 2, Beijing time, a total of 46,874,330 confirmed cases of new coronary pneumonia in the United States, and a total of 766,811 deaths. Compared with the data at 6:30 the previous day, there were 58,632 new confirmed cases and 545 new deaths in the United States.

2021-11-02

The total number of confirmed cases in France exceeds 7.15 million, and the health department confirms that the epidemic has rebounded again

China News Service, Paris, October 29 (Reporter Li Yang) On the 29th local time, the cumulative number of confirmed cases of new crown pneumonia in France exceeded 7.15 million; the French health department confirmed that the new crown epidemic had rebounded again on the same day. 　 　 French official data show that France has 6,433 new confirmed cases in a single day on the 29th, with a total of 7,153,188 confirmed cases. The cumulative number of deaths in France is now 117,649, with 27 new deaths. The number of hospitalized patients with the new crown in France is now 6,534, and the number of severely ill patients is 1,034. 　 The French Health Administration stated on the 29th that the rebound of the epidemic has been “confirmed” and the medical system can feel the impact of the rebound. In addition to the renewed increase in the number of infections, the number of hospitalized patients with the new crown and the number of severely ill patients have also risen again. According to a report issued by the French Health Agency that day, the incidence of new crowns has risen again at the national level. The average daily new confirmed cases in the previous week increased to 5276. The incidence of new crowns in France was 55 cases per 100,000 residents. , Exceeding the warning threshold of 50 infections per 100,000 residents. 　 　 The report stated that the admission rate of COVID-19 patients in all regions of mainland France remained stable or gradually increased. Among them, the relevant figures of the Paris Region, Provence-Alpes-Côte d'Azur and Central-Loire Valley ranked among the top in France. 　 　 In addition, the latest data from about 200 wastewater monitoring sites in France shows that more than half of the sites have observed an increase in the spread of the new crown virus, and the concentration of the new crown virus has increased in the Paris region and other places. This change has attracted the attention of experts. 　 　 The French Health Administration once again urges eligible vaccinators who have not yet received the new crown vaccine to get the vaccine as soon as possible, and those who are over 65 years old to get the third dose of vaccine as soon as possible; people must continue to observe preventive measures such as maintaining social distance. 　 　According to French official data, 51.14 million people in France have received at least one dose of the vaccine, accounting for 75.9% of the French population; 49.93 million people have completed two doses, accounting for 74.1% of the French population.

2021-10-30